1-20 of 35
Jun Guo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma

Jing Shi, Tao Jiao, Qian Guo, Weining Weng, Linjie Ma, Qing Zhang, Lijun Wang, Jianjian Zhang, Caiwei Chen, Yaling Huang, Mingqiao Wang, Rong Pan, Yanfang Tang, Wenhao Hu, Tao Meng, Shu-Hui Liu, Jun Guo, Yan Kong, Xun Meng
Journal: Cancer Research
Cancer Res (2023)
https://doi.org/10.1158/0008-5472.CAN-23-1356
Published: 05 September 2023
View article titled, A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma
Open the PDF for A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract CT208: Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: An open-label, single-arm, Phase 1 study

Si Lu, Yu Chen, Meiyu Fang, Zhengyun Zou, Di Wu, Zhiguo Luo, Jian Zhang, Jing Chen, Gang Huang, Hongming Pan, Xiubao Ren, Ying Cheng, Haichuan Su, Yuan Xin, Qiong Hua, Jianmei Hou, Jun Guo
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT208.
https://doi.org/10.1158/1538-7445.AM2023-CT208
Published: 14 April 2023
View article titled, Abstract CT208: Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: An open-label, single-arm, Phase 1 study
Journal Articles

Abstract P6-05-14: The association of sleep quality with anxiety, depression and social support in breast cancer patients with chemotherapy

Wenjuan Zhu, Wanling Li, Hui Yang, Linying Wang, Jun Guo, Jinnan Gao
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P6-05-14.
https://doi.org/10.1158/1538-7445.SABCS22-P6-05-14
Published: 01 March 2023
View article titled, Abstract P6-05-14: The association of sleep quality with anxiety, depression and social support in breast cancer patients with chemotherapy
Journal Articles

PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, Xue-Jun Guo, Jia-Le Tan, Xiao-Ting Cai, Yan Lin, Xinghua Pan, De-Hua Wu, Xue Bai, Zhong-Yi Dong
Journal: Cancer Research
Cancer Res (2023) 83 (4): 568–581.
https://doi.org/10.1158/0008-5472.CAN-22-1740
Published: 15 February 2023
View article titled, PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Open the PDF for PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract CT519: FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS mutations: A phase 1A dose-escalation study

Lili Mao, Jun Guo, Lingjun Zhu, Yu Jiang, Wangjun Yan, Jian Zhang, Ai-min Hui, Zhuli Wu, Yuchen Yang, Han Zhao, Yiqian Jiang, Lu Si
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT519.
https://doi.org/10.1158/1538-7445.AM2022-CT519
Published: 15 June 2022
View article titled, Abstract CT519: FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring <em>NRAS</em> mutations: A phase 1A dose-escalation study
Journal Articles

Abstract P2-13-33: Preclinical development of DHES0815A: A HER2-directed antibody-drug conjugate comprised of a reduced potency PBD dimer linked to a domain I binding HER2 antibody

Gail Lewis Phillips, Guangmin Li, Jun Guo, Shang-Fan Yu, Genee Lee, Donglu Zhang, Peter Dragovich, Thomas Pillow, Binqing Wei, M. Violet Lee, Ola Saad, Shab Masih, Douglas Leipold, Lisa Crocker, Melissa Schutten
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-33.
https://doi.org/10.1158/1538-7445.SABCS21-P2-13-33
Published: 15 February 2022
View article titled, Abstract P2-13-33: Preclinical development of DHES0815A: A HER2-directed antibody-drug conjugate comprised of a reduced potency PBD dimer linked to a domain I binding HER2 antibody
Journal Articles

Abstract CT035: Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study

Chuanliang Cui, Hongming Pan, Matteo Carlino, Jiuwei Cui, Xuan Wang, Cheng Chen, Xiao Xiang, Liu Yang, Jun Guo
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT035.
https://doi.org/10.1158/1538-7445.AM2021-CT035
Published: 01 July 2021
View article titled, Abstract CT035: Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Journal Articles

Abstract IA16: The landscape of mucosal melanoma: A long way to go

Jun Guo
Journal: Cancer Research
Cancer Res (2020) 80 (19_Supplement): IA16.
https://doi.org/10.1158/1538-7445.MEL2019-IA16
Published: 02 October 2020
View article titled, Abstract IA16: The landscape of mucosal melanoma: A long way to go
Journal Articles

Abstract 3423: HER2 amplification and microsatellite status distribution in Chinese gastric cancer patients

Jun Guo, Da Jiang, Wei Zhang, Ting Deng, Zhaojian Niu, Wenting Chen, Junping Shi, Shuirong Zhang, Lin Zhang
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3423.
https://doi.org/10.1158/1538-7445.AM2019-3423
Published: 01 July 2019
View article titled, Abstract 3423: <em>HER2</em> amplification and microsatellite status distribution in Chinese gastric cancer patients
Journal Articles

Abstract CT167: A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors

Jeffrey Goh, Ben Gao, Ben Markman, Hui Gan, Mark Voskoboynik, Yi-Long Wu, Jun Guo, Qing Zhou, Jun Zhao, Cheng Chen, Jingjun Qiu, Yingying Xu, Liu Yang, Michael Millward
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT167.
https://doi.org/10.1158/1538-7445.AM2019-CT167
Published: 01 July 2019
View article titled, Abstract CT167: A Phase Ib study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors
Journal Articles

Abstract 1369: Analysis of association between homologous recombination deficiency and tumor mutational burden in solid tumors

Hua Li, Liqun Wu, Tao Shou, Bo Jiang, Li Zhuang, Kunsong Li, Xiang Tan, Chao Guo, Weidong Guo, Yan Guan, Zheng Chen, Xiao Ding, Jun Guo, Zhenfang Du, Qiang Cui, Yue Che, Ming Yao
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1369.
https://doi.org/10.1158/1538-7445.AM2018-1369
Published: 01 July 2018
View article titled, Abstract 1369: Analysis of association between homologous recombination deficiency and tumor mutational burden in solid tumors
Journal Articles

Abstract 2783: Empowering therapeutic monoclonal antibodies with IFN-alpha for cancer immunotherapy

Jun Guo, Yu Xiao, Ramesh B. Lyer, Marc R. Lake, Uri S. Ladror, Xin Lu, Bill Pappano, John E. Harlan, Medha J. Tomlinson, Gail T. Bukofzer, Cherrie K. Donawho, Alexander R. Shoemaker, Tzu-Hsuan Huang
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2783.
https://doi.org/10.1158/1538-7445.AM2018-2783
Published: 01 July 2018
View article titled, Abstract 2783: Empowering therapeutic monoclonal antibodies with IFN-alpha for cancer immunotherapy
Journal Articles

Abstract 3495: Trip13, a target of miR192, facilitates colorectal cancer progression through WNT/β-catenin signaling

Sumit Agarwal, Balabhadrapatruni V. Chakravarthi, Darshan S. Chandrashekar, Rong Jun Guo, Pran Datta, Sooryanarayana Varambally, Upender Manne
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3495.
https://doi.org/10.1158/1538-7445.AM2018-3495
Published: 01 July 2018
View article titled, Abstract 3495: Trip13, a target of miR192, facilitates colorectal cancer progression through WNT/β-catenin signaling
Journal Articles

Abstract 4349: Higher level of tumor mutational burden and 11q13 amplification in Chinese hepatocellular carcinoma patients

Xiaofeng Tang, Le Fan, Gang Chen, Weidong Guo, Fabo Qiu, Jun Wang, Jun Guo, Lijuan Chen, Peng Zhang, Weiwei Shi, Kai Wang, Weifeng Wang
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4349.
https://doi.org/10.1158/1538-7445.AM2018-4349
Published: 01 July 2018
View article titled, Abstract 4349: Higher level of tumor mutational burden and 11q13 amplification in Chinese hepatocellular carcinoma patients
Journal Articles

Abstract 4335: High incidence of POLE and POLD1 mutations in Chinese colorectal cancer patients identified by comprehensive genomic profiling

Yinbo Chen, Sen Zhang, Wei Huang, Jun Guo, Weidong Guo, Fabo Qiu, Meihai Deng, Jingyu Cao, Samuel J. Klempner, Shun Yao, Jicheng Yao, Shou Mu, Ming Yao, Kai Wang, Weifeng Wang
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4335.
https://doi.org/10.1158/1538-7445.AM2018-4335
Published: 01 July 2018
View article titled, Abstract 4335: High incidence of <em>POLE</em> and <em>POLD1</em> mutations in Chinese colorectal cancer patients identified by comprehensive genomic profiling
Journal Articles

Abstract 2127: Identification of a novel NAMPT inhibition resistance mechanism utilizing the de novo NAD+ biosynthesis pathway

jun guo, Chris Tse, William N. Pappano
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2127.
https://doi.org/10.1158/1538-7445.AM2016-2127
Published: 15 July 2016
View article titled, Abstract 2127: Identification of a novel NAMPT inhibition resistance mechanism utilizing the de novo NAD+ biosynthesis pathway
Journal Articles

Abstract 2303: The expression of gangliosides GD2 is associated with worse prognosis in melanoma patients

Yan Kong, Jiayi Yu, Lu Si, Zhihong Chi, Chuanliang Cui, Xinan Sheng, Jun Guo
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2303.
https://doi.org/10.1158/1538-7445.AM2016-2303
Published: 15 July 2016
View article titled, Abstract 2303: The expression of gangliosides GD2 is associated with worse prognosis in melanoma patients
Journal Articles

Abstract 1207: Preclinical development of 2nd generation HER2-directed antibody-drug conjugates

Gail D. Lewis Phillips, Guangmin Li, Jun Guo, Jeffrey Lau, Shang-Fan Yu, Thomas Pillow, Byoung-Chul Lee, Jack Sadowsky, Melissa Schutten, Carter Fields, Mark X. Sliwkowski
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1207.
https://doi.org/10.1158/1538-7445.AM2016-1207
Published: 15 July 2016
View article titled, Abstract 1207: Preclinical development of 2nd generation HER2-directed antibody-drug conjugates
Journal Articles

Abstract 5532: Discovery of A-366, a novel small molecule inhibitor that uncovers an unappreciated role for G9a/GLP in the epigenetics of leukemia

Jun Guo, Marina Pliushchev, Yupeng He, Debra Ferguson, Sujatha Jagadeeswaran, Andrew Petros, Chaohong Sun, Niru B. Soni, Bailin Shaw, Alla Korepanova, David Maag, Ramzi Sweis, Fritz G. Buchanan, Michael Michaelides, Alex Shoemaker, Chris Tse, Gary G. Chiang, William N. Pappano
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5532.
https://doi.org/10.1158/1538-7445.AM2014-5532
Published: 01 October 2014
View article titled, Abstract 5532: Discovery of A-366, a novel small molecule inhibitor that uncovers an unappreciated role for G9a/GLP in the epigenetics of leukemia
Journal Articles

Abstract 3450: ABT-348 in combination with inhibition of CDK4/6 highlights a strategy to target RB mutant cells while sparing RB wild-type cells.

Jun Guo, Michael L. Curtin, Zehan Chen, Daniel H. Albert, Paul Tapang, Yujia Dai, Mia-Ha Bui, Peter Kovar, Michael R. Michaelides, Keith B. Glaser, Chris Tse, O. Jameel Shah
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3450.
https://doi.org/10.1158/1538-7445.AM2013-3450
Published: 15 April 2013
View article titled, Abstract 3450: ABT-348 in combination with inhibition of CDK4/6 highlights a strategy to target RB mutant cells while sparing RB wild-type cells.